Latest News

RIVERSIDE, Calif. — Imagine if we could inhale scents that delay the onset of cancer, inflammation, or neurodegenerative disease. Researchers at the University of California, Riverside, are poised to bring this futuristic technology closer to reality. In lab experiments, a team led by Anandasankar Ray, a professor of molecular, cell and systems...
PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical...
Villejuif, France – Aglaia Therapeutics, a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, today announces the successful completion of a €4M ($4.7M) seed funding round. Advent France Biotechnology (AFB) led the round, with the participation of Crédit Mutuel Innovation and Pierre Fabre. AFB also acted...
Boston, MA – A significant survival improvement for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia is published today by the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910 (NCT02003222), which evaluated blinatumomab immunotherapy in patients who were in remission...